The Broad Concept of "Spasticity-Plus Syndrome" in Multiple Sclerosis: A Possible New Concept in the Management of Multiple Sclerosis Symptoms

Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto, Lluis Ramió, Óscar Fernández, Lucienne Costa-Frossard, Marisa Martínez-Ginés, Paloma Montero, José Maria Prieto, Lluis Ramió

Abstract

Multiple sclerosis (MS) pathology progressively affects multiple central nervous system (CNS) areas. Due to this fact, MS produces a wide array of symptoms. Symptomatic therapy of one MS symptom can cause or worsen other unwanted symptoms (anticholinergics used for bladder dysfunction produce impairment of cognition, many MS drugs produce erectile dysfunction, etc.). Appropriate symptomatic therapy is an unmet need. Several important functions/symptoms (muscle tone, sleep, bladder, pain) are mediated, in great part, in the brainstem. Cannabinoid receptors are distributed throughout the CNS irregularly: There is an accumulation of CB1 and CB2 receptors in the brainstem. Nabiximols (a combination of THC and CBD oromucosal spray) interact with both CB1 and CB2 receptors. In several clinical trials with Nabiximols for MS spasticity, the investigators report improvement not only in spasticity itself, but also in several functions/symptoms mentioned before (spasms, cramps, pain, gait, sleep, bladder function, fatigue, and possibly tremor). We can conceptualize and, therefore, hypothesize, through this indirect information, that it could be considered the existence of a broad "Spasticity-Plus Syndrome" that involves, a cluster of symptoms apart from spasticity itself, the rest of the mentioned functions/symptoms, probably because they are interlinked after the increase of muscle tone and mediated, at least in part, in the same or close areas of the brainstem. If this holds true, there exists the possibility to treat several spasticity-related symptoms induced by MS pathology with a single therapy, which would permit to avoid the unnecessary adverse effects produced by polytherapy. This would result in an important advance in the symptomatic management of MS.

Keywords: multiple sclerosis; spasticity; symptom cluster; symptomatic therapy; symptomatic treatment.

Copyright © 2020 Fernández, Costa-Frossard, Martínez-Ginés, Montero, Prieto and Ramió.

Figures

Figure 1
Figure 1
Spasticity prevalence according to disease duration in years (N = 23,842). With permission (9).
Figure 2
Figure 2
Symptom reduction priorities for patients. With permission (18).
Figure 3
Figure 3
Areas of the CNS mediating spasticity.
Figure 4
Figure 4
Distribution of cannabinoid receptors (CB1 and CB2) in the central nervous system (The Endocannabinoid System). Redrawn from https://www.fundacion-canna.es/en/endocannabinoid-system. Accessed April 06, 2019). With permission.

References

    1. Ransohoff RM, Hafler DA, Lucchinetti CF. Multiple sclerosis-a quiet revolution. Nat Rev Neurol. (2015) 11:134–42. 10.1038/nrneurol.2015.14
    1. Lunde HMB, Assmus J, Myhr K-M, Bø L, Grytten N. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatr. (2017) 88:621–5. 10.1136/jnnp-2016-315238
    1. Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis–clinical characteristics, treatment and quality of life. Acta Neurol Scand. (2014) 129:154–62. 10.1111/ane.12202
    1. Fox RJ, Thompson A, Baker D, Baneke P, Brown D, Browne P, et al. . Setting a research agenda for progressive multiple sclerosis: the international collaborative on progressive MS. Mult Scler. (2012) 18:1534–40. 10.1177/1352458512458169
    1. Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. Mt Sinai J Med. (2011) 78:176–91. 10.1002/msj.20245
    1. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. (2010) 9:1182–99. 10.1016/S1474-4422(10)70249-0
    1. Toosy A, Ciccarelli O, Thompson A. Symptomatic treatment and management of multiple sclerosis. In: Goodin DS, editor. Handbook of Clinical Neurology Multiple Sclerosis Related Disorders, 3rd series, Vol. 122 Amsterdam: Elsevier B.V; (2014). p. 514–61.
    1. Marková J. Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials. Neurodegener Dis Manag. (2019) 9:9–13. 10.2217/nmt-2018-0050
    1. Kister I, Bacon TE, Chamot E, Salter AR, Cutter GR, Kalina JT, et al. . Natural history of multiple sclerosis symptoms. Int J MS Care. (2013) 15:146–56. 10.7224/1537-2073.2012-053
    1. Sastre-Garriga J, Tintoré M, Nos C, Tur C, Río J, Téllez N, et al. . Clinical features of CIS of the brainstem/cerebellum of the kind seen in MS. J Neurol. (2010) 257:742–6. 10.1007/s00415-009-5403-0
    1. Nociti V, Losavio FA, Gnoni V, Losurdo A, Testani E, Vollono C, et al. . Sleep and fatigue in multiple sclerosis: a questionnaire-based, cross-sectional, cohort study. J Neurol Sci. (2017) 372:387–92. 10.1016/j.jns.2016.10.040
    1. Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler Houndmills Basingstoke Engl. (2004) 10:589–95. 10.1191/1352458504ms1085oa
    1. Milinis K, Tennant A, Young CA, TONiC study group . spasticity in multiple sclerosis: associations with impairments and overall quality of life. Mult Scler Relat Disord. (2016). 5:34–9. 10.1016/j.msard.2015.10.007
    1. Barnes MP, Kent RM, Semlyen JK, McMullen KM. Spasticity in multiple sclerosis. Neurorehabil Neural Repair. (2003) 17:66–70. 10.1177/0888439002250449
    1. Sosnoff JJ, Gappmaier E, Frame A, Motl RW. Influence of spasticity on mobility and balance in persons with multiple sclerosis. J Neurol Phys Ther JNPT. (2011) 35:129–32. 10.1097/NPT.0b013e31822a8c40
    1. Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. (2009) 26:1043–57. 10.1007/s12325-009-0082-x
    1. Heesen C, Böhm J, Reich C, Kasper J, Goebel M, Gold SM. Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable. Mult Scler Houndmills Basingstoke Engl. (2008) 14:988–91. 10.1177/1352458508088916
    1. Heller M, Taylor D. Greater Expectations: The Future Hopes of People With Multiple Sclerosis. (2017). Available online at:
    1. Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int J Neurosci. (2013) 123:400–8. 10.3109/00207454.2012.762364
    1. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. (2007) 24:CD005029 10.1002/14651858.CD005029.pub2
    1. Alusi SH, Worthington J, Glickman S, Bain PG. A study of tremor in multiple sclerosis. Brain J Neurol. (2001) 124:720–30. 10.1093/brain/124.4.720
    1. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. (2003) 63:153–66. 10.2165/00003495-200363020-00003
    1. Tepavcevic DK, Kostic J, Basuroski ID, Stojsavljevic N, Pekmezovic T, Drulovic J. The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. (2008) 14:1131–6. 10.1177/1352458508093619
    1. Nortvedt MW, Riise T, Myhr KM, Landtblom AM, Bakke A, Nyland HI. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler Houndmills Basingstoke Engl. (2001) 7:231–5. 10.1177/135245850100700404
    1. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. a population survey. Gastroenterology. (1990) 98:1538–42. 10.1016/0016-5085(90)91087-M
    1. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. (2003) 9:219–27. 10.1191/1352458503ms904oa
    1. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. (2008) 7:1139–51. 10.1016/S1474-4422(08)70259-X
    1. Kalia LV, O'Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler. (2005) 11:322–7. 10.1191/1352458505ms1168oa
    1. Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J Neurol. (2010) 257:926–36. 10.1007/s00415-009-5441-7
    1. Amatya B, Khan F, Galea M. Rehabilitation for people with multiple sclerosis: an overview of cochrane reviews. Cochr Database of Syst Rev. (2019) 1:CD012732. 10.1002/14651858.CD012732.pub2
    1. Newsome SD, Aliotta PJ, Bainbridge J, Bennett SE, Cutter G, Fenton K, et al. . A framework of care in multiple sclerosis, part 2: symptomatic care and beyond. Int J MS Care. (2017) 19:42–56. 10.7224/1537-2073.2016-062
    1. Oreja-Guevara C, Montalban X, de Andrés C, Casanova-Estruch B, Muñoz-García D, García I, et al. . Consensus document on spasticity in patients with multiple sclerosis. grupo de enfermedades desmielinizantes de la sociedad española de neurología. Rev Neurol. (2013) 57:359–73. 10.33588/rn.5708.2013374
    1. Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. (2009) 6:96–107. 10.1038/ncpuro1298
    1. The British Medical Association Illustrated Medical Dictionary. London: Dorling Kindersley; (2002). p. 177–536.
    1. Patejdl R, Zettl UK. Spasticity in multiple sclerosis: contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions. Autoimmun Rev. (2017) 16:925–36. 10.1016/j.autrev.2017.07.004
    1. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatr. (1993) 56:245–50. 10.1136/jnnp.56.3.245
    1. Patejdl R, Penner IK, Noack TK, Zettl UK. Multiple sclerosis and fatigue: a review on the contribution of inflammation and immune-mediated neurodegeneration. Autoimmun Rev. (2016) 15:210–20. 10.1016/j.autrev.2015.11.005
    1. Motl RW, Suh Y, Weikert M. Symptom cluster and quality of life in multiple sclerosis. J Pain Symptom Manage. (2010) 39:1025–32. 10.1016/j.jpainsymman.2009.11.312
    1. Svízenská I, Dubový P, Sulcová A. Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures–a short review. Pharmacol Biochem Behav. (2008) 90:501–11. 10.1016/j.pbb.2008.05.010
    1. Howlett AC. The cannabinoid receptors. Prostaglandins Other Lipid Mediat. (2002) 68–69:619–31. 10.1016/S0090-6980(02)00060-6
    1. van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, et al. . Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science. (2005) 310:329–32. 10.1126/science.1115740
    1. Baker D, Jackson SJ, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol. (2007) 152:649–54. 10.1038/sj.bjp.0707458
    1. Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms inmultiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. (2004) 10:434–41. 10.1191/1352458504ms1082oa
    1. Collin C, Davies P, Mutiboko IK, Ratcliffe S. Sativex spasticity in MS study group. randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol. (2007) 14:290–6. 10.1111/j.1468-1331.2006.01639.x
    1. Collin C, Ehler E, Waberzinek G, Alsindi Z, Davies P, Powell K, et al. . A double-blind, randomized, placebo-controlled, parallel-group study of sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res. (2010) 32:451–9. 10.1179/016164109X12590518685660
    1. Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. . A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. (2011) 18:1122–31. 10.1111/j.1468-1331.2010.03328.x
    1. Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, et al. . Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci. (2019) 129:119–28. 10.1080/00207454.2018.1481066
    1. Fernández O. Advances in the management of MS spasticity: recent observational studies. Eur Neurol. (2014) 72(Suppl. 1):12–4. 10.1159/000367618
    1. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. . Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. (2003) 362:1517–26. 10.1016/S0140-6736(03)14738-1
    1. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. (2006) 17:636–41. 10.1007/s00192-006-0086-x
    1. Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ. Randomized controlled trial of sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. (2010) 16:1349–59. 10.1177/1352458510378020
    1. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. (2007) 23:17–24. 10.1185/030079906X158066
    1. Arroyo R, Vila C, Dechant KL. Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity. J Comp Eff Res. (2014) 3:435–44. 10.2217/cer.14.30

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir